Primary Erythromelalgia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The global erythromelalgia treatment market reach USD 1.98 Billion in 2022 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2032

United statesUnited kingdomAsia pacificXenon pharmaceuticals incPfizer incDrug administrationRoute of administrationTeva pharmaceutical industries ltdErythromelalgia treatmentQuince marketKey playersTreatment marketPrimary erythromelalgiaBefore buying this reportSpecialty clinicsHospital pharmacies